COMPASS Pathways announces pricing of public offering
London, UK, 30 April 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq:CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its public offering of 4,000,000 American Depositary Shares (“ADSs”) representing 4,000,000 ordinary shares at a public offering price of $36.00 per […]
BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its novel implantable subcutaneous product and its use in the prevention of […]
Tryp Therapeutics Announces Q2 2021 Financial Results
San Diego, California–(Newsfile Corp. – April 29, 2021) – Tryp Therapeutics Inc. (CNSX:TRYP.CN) (” Tryp ” or the ” Company “), today announced its interim financial results for the three and six month periods ended February 28, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and […]
Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds
Toronto, Ontario–(Newsfile Corp. – April 29, 2021) – Mindset Pharma Inc. (CNSX:MSET.CN) (FSE:9DF) (OTCQB:MSSTF) (” Mindset ” or the ” Company “) is pleased to announce that certain of Mindset’s Family 4 compounds, a group of patent-pending novel chemical entities that are inspired by DMT & 5-MeO-DMT, are exhibiting positive in vitro screening characteristics. James Lanthier, CEO of Mindset, commented, “N,N-dimethyltryptamine (DMT) & […]
Core One Labs Reaches Definitive Agreement to Acquire Akome Biotech
Core One Labs Inc. (CNSX:COOL.CN), (OTC:CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”), a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has entered into a definitive share purchase agreement (the “Definitive Agreement”), dated April 23, 2021, pursuant to which it will acquire all […]
